Interaction of antibody and cell surface localized antigen
✍ Scribed by E. Yefenof; I. P. Witz; E. Klein
- Publisher
- John Wiley and Sons
- Year
- 1976
- Tongue
- French
- Weight
- 561 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The changes occurring in the expression of a membrane‐associated antigen following binding of specific antibodies and the fate of the bound antibodies were investigated. Daudi cells, carrying membrane 7S IgM molecules, were coated with radio‐labelled anti‐IgM antibodies and incubated under culture conditions at 37°C. Within 10 h, more than 80% of the cell‐bound radioactivity was shed from the cells into the culture medium. Concomitantly, IgM molecules were lost, as the cells had a diminished ability to bind a new aliquot of antibody. This phenomenon occurred also when the antibody was used at a low concentration, i.e. did not saturate the cell‐surface antigens. The precipitability of the antibody released from the cells with 10% TCA and 40% saturated ammonium sulphate was lower than that of native antibody, indicating some degradation. Also, shed antibody could rebind to fresh Daudi cells less efficiently than native antibody. The presence of immune complexes in the culture supernatants was indicated by the following results: (1) some of the shed radioactivity could bind to IgM‐negative but Fc receptor‐bearing cells; and (2) immune precipitates of sheep anti‐IgM shed from ^3^H‐leucine labelled Daudi cells and of rabbit anti‐sheep IgG antibodies contained ^3^H activity.
📜 SIMILAR VOLUMES
## Abstract Sera of 200 non‐transfused healthy male blood donors were tested for antibody reactivity to cell‐surface antigens of cultured astrocytoma cells. Positive reactions were observed only rarely by protein‐A assay (PA), in about half the cases by immune adherence assay (IA) and in nearly all
## Abstract A panel of 3 monoclonal antibodies (MAbs) directed against human lung tumour cell‐surface antigens has been produced following immunizations with the established small‐cell lung cancer (SCLC) cell line, NCl‐H69, and with another SCLC cell line, COR‐L32, recently derived from clinical ma